GlobalData analyst Shehroz Mahmood notes that Novo Nordisk's amycretin could become the "next frontier" in obesity and T2D.

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Belite Bio’s ophthalmology asset, tinlarebant, could become the first US-approved treatment for STDG1, following the positive results of the Phase III DRAGON study. Image credit: Edgar Martirosyan via ...

Produodopa is an alternative to AbbVie’s own Duodopa. Credit: Michael Vi via Shutterstock. On 9 January 2024, AbbVie announced the launch of Produodopa ...

Takeda Pharmaceuticals’ dengue vaccine, Qdenga, has demonstrated long-term efficacy in preventing infections and hospitalisations in a seven-year Phase III study. Image credit: SILVIA MAQQ via ...

Kelun-Biotech’s Sac-TMT has met its primary endpoint of PFS improvements in combination with MSD’s Keytruda in comparison to the checkpoint inhibitor alone in a Phase III trial. Image credit: Butusova ...

Novartis’ RLT received US FDA approval for earlier use in mCRPC. Credit: Konektus Photo/Shutterstock. Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified ...

Contineum Therapeutics’ M1 antagonist, PIPE-307, has failed to meet its primary and secondary efficacy endpoints in a Phase II trial in RRMS. Image credit: Andrzej Rostek via ShutterStock.com.

Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...

The never-ending challenge of finding and recruiting eligible clinical trial participants continues to push sponsors to find new avenues to expedite enrolment. As decentralisation shakes up ...

In 2018, roughly a year before the World Health Organization declared Covid-19 a global health emergency, a conference in Edinburgh imagined a very different type of medical crisis: during a ...